4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
iBio, Inc. (IBIO) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 23 employees. Its market capitalization is roughly $40 million. In the fiscal year ended 2026-06-30, IBIO reported $0M in revenue and ($33M) in net income.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Interactive charts & full statements → Open the IBIO valuation workbench →
| Income statement | TTM → 2026-06-30 | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | — | — | — | — | $2M |
| Operating Income (EBIT) | ($35M) | ($35M) | ($19M) | ($17M) | ($29M) | — |
| Net Income | ($33M) | ($33M) | ($18M) | ($25M) | ($65M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($11M) | ($8M) | ($9M) | ($6M) | ($5M) | — |
| Net Income | ($11M) | ($8M) | ($9M) | ($6M) | ($5M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets | $99M | $23M | $29M | $41M | — |
| Total Liabilities | $13M | $8M | $7M | $26M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IBIO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms